开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 12-05 16:09:06

1.980

-0.030

-1.49%

最高2.000	最低1.940	成交量103.75万
今开1.990	昨收2.010	日振幅2.99%
总市值9.88亿	流通市值9.88亿	总股本4.99亿
成交额204.01万	换手率0.21%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.98,"timestamp":1764922146583,"preClose":2.01,"halted":0,"volume":1037500,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.3970779500910831,"marketStatus":"休市中","change":-0.03,"latestTime":"12-05 16:09:06","open":1.99,"high":2,"low":1.94,"amount":2040120,"amplitude":0.029851,"askPrice":1.98,"askSize":4500,"bidPrice":1.95,"bidSize":91500,"shortable":0,"etf":0,"ttmEps":-0.42538598657885307,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.01,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":1.239249880539426,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2589954058","title":"现金告急、管线存疑、估值承压：科望医药三闯港交所背后","url":"https://stock-news.laohu8.com/highlight/detail?id=2589954058","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589954058?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:13","pubTimestamp":1764929580,"startTime":"0","endTime":"0","summary":"港交所信息显示，临床阶段生物医药企业科望医药已于2025年11月27日第三次向港交所主板递交上市申请。这家成立8年、累计亏损超20亿元的创新药企，在现金仅能支撑3个月研发的紧迫局面下，再次向资本市场发起冲刺。其背后虽站着礼来亚洲基金、高瓴、腾讯等明星投资机构，但重重风险已难以掩盖。　　科望医药正面临严峻的资金链考验。在现金即将耗尽、负债高企、管线尚未证明价值的重重压力下，此次IPO已不仅是发展问题，更是生存问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-05/doc-infztyiw9823658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","HEXmain","09939","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2589860931","title":"中银国际：26年建议关注医疗服务板块的机会 看好医药板块创新、出海、消费三个方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589860931?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:46","pubTimestamp":1764924369,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中银国际发布研报称，25年医疗行业各子板块涨幅分化明显，其中CXO以及创新药相关的板块涨幅较大，26年该行仍然看好依靠“产品驱动”的相关公司，核心在于“产品驱动”相关公司的产业趋势仍然向好，相关标的有望逐步进入盈利周期;除此之外，26年建议关注医疗服务板块的机会，虽然25年医疗服务板块表现并不亮眼，但该行认为医疗服务的长期逻辑仍在，且行业发展具备韧性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"2589816871","title":"开拓药业-B12月05日遭主力抛售77.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589816871","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589816871?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:15","pubTimestamp":1764922559,"startTime":"0","endTime":"0","summary":"12月05日, 开拓药业-B股价跌1.49%，报收1.98元，成交金额204.0万元，换手率0.21%，振幅2.99%，量比1.24。开拓药业-B今日主力资金净流出77.4万元，连续3日净流出，上一交易日主力净流出19.2万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为40.00%，平均跌幅为11.51%。该股近5个交易日下跌2.94%，主力资金累计净流出136.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入16.1万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120516220597917a8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120516220597917a8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2589846770","title":"同源康医药-B12月05日获主力加仓1031.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589846770","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589846770?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:15","pubTimestamp":1764922550,"startTime":"0","endTime":"0","summary":"12月05日, 同源康医药-B股价涨5.58%，报收14.00元，成交金额1.9亿元，换手率3.64%，振幅15.08%，量比5.23。同源康医药-B今日主力资金净流入1031.8万元，上一交易日主力净流入708.7万元。该股近5个交易日下跌0.07%，主力资金累计净流入1694.3万元；近20日主力资金累计净流入1748.7万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205162043a7257f62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205162043a7257f62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02410","BK1515","09939"],"gpt_icon":0},{"id":"2589861273","title":"科望医药ESMO Asia口头报告公布全球首创ES014单药疗法Ⅰ期亮眼数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589861273","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589861273?lang=zh_cn&edition=full","pubTime":"2025-12-05 15:18","pubTimestamp":1764919101,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年12月5日，科望医药于欧洲肿瘤内科学会亚洲年会通过口头报告公布其自主研发的双特异性抗体ES014的Ⅰ期临床试验结果。ES014是科望医药自主研发的全球首创、也是全球首个进入临床阶段的CD39/TGFβ双特异性抗体，在多个具有高度未满足临床需求的肿瘤类型中呈现出初步且具有临床意义的抗肿瘤活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"2589861334","title":"港股异动 | 同源康医药-B(02410)盘中涨超12% 市场关注核心产品TY-9591进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2589861334","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589861334?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:58","pubTimestamp":1764917919,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B盘中涨超12%，截至发稿，涨7.16%，报14.21港元，成交额1.32亿港元。消息面上，在今年9月份的世界肺癌大会上，同源康医药发布的艾多替尼片针对非小细胞肺癌脑转移关键Ⅱ期临床试验引起同行高度关注。据悉，艾多替尼片是同源康医药针对EGFR经典突变开发的高选择性小分子抑制剂，公司已于2024年11月完成附条件批准上市资格的224例患者入组，并已于2025年4月提交预上市申请，预计2025年4季度正式提交附条件上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","TY","09939","02410","BK1515","BK1161"],"gpt_icon":0},{"id":"2589895247","title":"12月医药再融资行情升温，押注创新药成共识","url":"https://stock-news.laohu8.com/highlight/detail?id=2589895247","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589895247?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:55","pubTimestamp":1764899728,"startTime":"0","endTime":"0","summary":"12月以来，医药企业融资密集。12月4日，国际医学公告称，公司拟定增募资不超10.08亿元。12月3日，佐力药业公告称，拟发行可转债募资不超15.56亿元。据了解，今年以来众多创新药企业都进行了不少再融资行为。2月，迪哲医药发布公告，公司定增方案已经获证监会注册，迪哲医药计划募资金额不超过18.5亿元。而募资普遍投向创新药领域，则深刻反映了行业受国家明确鼓励与引导资源向研发创新集聚发展的共识。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512050959319790e6b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512050959319790e6b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0359201612.USD","BK1574","LU0359202008.SGD","BK1515","09939","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD","06978","BK1191","01276"],"gpt_icon":0},{"id":"2589885635","title":"劲方医药-B(02595)：GFH375治疗转移性胰腺癌注册性临床试验在首家研究中心启动 为全球首个口服KRAS G12D抑制剂单药对照化疗III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2589885635","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589885635?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:16","pubTimestamp":1764893771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，口服KRAS G12D 抑制剂GFH375治疗经治 KRAS G12D突变型转移性胰腺癌患者的注册性III期试验已在北京大学肿瘤医院启动。这项多中心、开放标签、随机对照的III期试验将在约40家中心开展，计划入组约320例既往接受至少一种标准系统性治疗的转移性胰腺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02595","09939","BK1161","BK1574","159938","BK4134","BK1515"],"gpt_icon":0},{"id":"2589852136","title":"上海君实生物医药科技股份有限公司发布2025年11月证券变动月报","url":"https://stock-news.laohu8.com/highlight/detail?id=2589852136","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589852136?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:55","pubTimestamp":1764892514,"startTime":"0","endTime":"0","summary":"中访网数据  上海君实生物医药科技股份有限公司于2025年12月4日向香港交易及结算所有限公司提交了截至2025年11月30日的证券变动月报表。报告显示，公司法定股本及已发行股份在本月内保持稳定，未发生变动。截至11月底，公司法定/注册股本总额为人民币1,026,689,871元。根据公司股份期权计划，截至11月底，根据H股股票期权激励计划授出的期权数目为13,210,000份，本月无变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205080055a7249b9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205080055a7249b9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1161","BK1583","09939","BK1515","BK1574"],"gpt_icon":0},{"id":"2589852250","title":"12月5日热门路演速递 | 政策、医药、宏观、旅游，四维共振前瞻2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589852250","media":"Wind万得","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589852250?lang=zh_cn&edition=full","pubTime":"2025-12-05 06:31","pubTimestamp":1764887460,"startTime":"0","endTime":"0","summary":"01“金秋万象启 风起新程远”——东莞证券2026年投资策略报告会（下）19:30-11:30核心看点：政策与事件将引爆哪些新主线？东莞证券2026策略下半场发问：资金如何布局政策风口？嘉宾：张瑜 | 华创证券研究所副所长、宏观首席分析师 扫码预约04途牛[TOUR.O]2025年第三季度业绩交流会21:00-22:00核心看点：途牛如何破局出境游复苏？嘉宾：途牛核心管理层扫码预约现在打开万得 3C 会议平台，搜索会议名称即可完成预约。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5ODQ4MjgyMQ==&mid=2651335157&idx=4&sn=d07975536e7ee3601e6c0820d7868a2e&chksm=bccd05a18f13a81d7811ca6ccf20a2d24c88febb6fcb05d3ea032a1bdbe2cb805c09537d1f0f&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","09939","159938","BK1161","BK1515"],"gpt_icon":0},{"id":"2589858430","title":"创胜集团-B(06628)：创胜医药于ESMO Asia公布osemitamab三联疗法一线治疗胃或胃食管结合部腺癌的I/II期(Transtar102)更新疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589858430","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589858430?lang=zh_cn&edition=full","pubTime":"2025-12-05 06:25","pubTimestamp":1764887126,"startTime":"0","endTime":"0","summary":"创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床试验(Transtar102)G \n队列基于CLDN18.2和PD-L1表达的更新疗效分析。该研究结果以壁报形式(摘要编号：#299P)亮相于在新加坡举行的欧洲肿瘤内科学会亚洲年会(ESMO \nAsia Congress 2025)。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_12.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_12.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","159938","06628","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"2588884617","title":"河化股份：子公司产品应用于医药制药行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588884617?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:52","pubTimestamp":1764852725,"startTime":"0","endTime":"0","summary":"证券之星消息，河化股份(000953)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司精细类化工可以应用在哪些领域？河化股份回复：您好！公司子公司南松医药的医药中间体等精细化工产品，主要应用于医药制药等行业。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400036952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0071","BK0239","01477","BK1161","BK0066","BK1191","BK1574","000953","BK0004","09939","BK0010","BK1515","159938"],"gpt_icon":0},{"id":"2589383664","title":"百奥赛图连续三年荣获“最具价值医药及医疗公司”奖项，彰显卓越创新实力与行业影响力","url":"https://stock-news.laohu8.com/highlight/detail?id=2589383664","media":"百奥赛图","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589383664?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:00","pubTimestamp":1764846017,"startTime":"0","endTime":"0","summary":"2025年12月3日，在由智通财经与新智基金网联合主办、冬日暖阳 Donova 独家承办的 “第十届智通财经上市公司颁奖盛典” 上，百奥赛图再次荣获“最具价值医药及医疗公司”奖项。百奥赛图采用开放灵活的模式持续推进全球商务合作，截至2025年上半年，公司累计签署约300项抗体合作协议，成为全球抗体药物研发的重要赋能者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200217a4cc9c7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204200217a4cc9c7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02315","09939","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2588004460","title":"开拓药业-B12月04日遭主力抛售19.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588004460","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588004460?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:15","pubTimestamp":1764836143,"startTime":"0","endTime":"0","summary":"12月04日, 开拓药业-B股价跌0.50%，报收2.01元，成交金额248.2万元，换手率0.25%，振幅4.46%，量比1.16。开拓药业-B今日主力资金净流出19.2万元，上一交易日主力净流出39.6万元。该股近5个交易日下跌6.51%，主力资金累计净流出58.8万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入93.5万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161904a7234f4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161904a7234f4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2588005836","title":"科望医药成立8年累计亏损超20亿 现金3300万负债27亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2588005836","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588005836?lang=zh_cn&edition=full","pubTime":"2025-12-04 14:34","pubTimestamp":1764830058,"startTime":"0","endTime":"0","summary":"中国经济网编者按：据21世纪经济报道12月3日发布的报道《科望医药三闯港交所持续亏损，明星资本押注双抗能否破局？》，这家成立8年、累计亏损超20亿元的创新药企，正带着仅够支撑3个月研发的现金储备，在“不上市即破产”的压力下再度冲刺资本市场。　　报道指出，科望医药资本续命倒计时：3300万现金对峙27亿负债。截至2024年末，公司现金及现金等价物仅余3282万元，较上年同期的2.7亿元大幅缩水88%，而同期研发成本仍达1.17亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251204/31844036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","159938","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"2588074906","title":"医药股普遍回暖 荣昌生物(09995)涨4.26% 交银国际料明年内地医药板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2588074906","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588074906?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:58","pubTimestamp":1764817092,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍回暖，荣昌生物 涨4.26%，康方生物涨3.89%，金斯瑞生物科技涨3.11%，康诺亚-B涨2.95%，科伦博泰生物-B涨2.45%，诺诚健华涨1.79%，药明生物涨1.63%，泰格医药涨1.38%，药明康德涨1.33% 。交银国际发表报告指，予内地医药行业领先评级。如该行此前预期，内地医药行业2025年迎来关键转折。2026年，该行认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970883","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0856984785.SGD","LU2399975544.HKD","02359","LU0588546209.SGD","09969","LU2476274720.SGD","09926","LU0634319403.HKD","BK1587","BK0239","LU0823426308.USD","LU2488822045.USD","LU0359202008.SGD","LU1961090484.USD","688331","BK1589","LU0181495838.USD","BK1515","LU0326950275.SGD","LU0819121731.USD","IE00BPRC5H50.USD","LU0307460666.USD","LU1720050803.USD","LU0359201612.USD","LU0417516571.SGD","BK1141","01548","BK1574","09995","BK1610","LU0561508036.HKD","LU1688375341.USD","03329","LU0052750758.USD","06990","LU2242644610.SGD","LU0516423091.SGD","LU1880383366.USD","LU0516422952.EUR","02162","159938","02269","09939","HK0000320264.USD","LU2148510915.USD","03347","LU2039709279.SGD","LU1046422090.SGD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2588890072","title":"医药流通板块短线拉升，瑞康医药涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2588890072","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588890072?lang=zh_cn&edition=full","pubTime":"2025-12-04 10:38","pubTimestamp":1764815880,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月4日，医药流通板块短线拉升，瑞康医药涨停，药易购、海王生物、国科恒泰、合富中国、开开实业等跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-04/doc-infzqyfk9416283.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-04/doc-infzqyfk9416283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0185","BK0077","159938","BK1574","BK0197","BK0132","BK1161","002589","09939","BK0250","BK1515","BK0070"],"gpt_icon":0},{"id":"1184350727","title":"港股生物医药股表现活跃！心玮医疗-B涨近5%，歌礼制药-B涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184350727","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184350727?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:43","pubTimestamp":1764812582,"startTime":"0","endTime":"0","summary":"12月4日，港股$生物(000504)$医药股盘初表现活跃，$心玮医疗-B(06609)$涨近5%，$歌礼制药-B(01672)$涨超4%，$嘉和生物-B(06998)$涨近3%，$康方生物(09926)$、$荣昌生物(09995)$涨超2%>>","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"78017fe3ba4f859116cb01c02d313574","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","LU0348783233.USD","LU2328871848.SGD","LU0348825331.USD","LU0348767384.USD","06609","LU0348784397.USD","LU0417516738.SGD","LU2476274308.USD","BK1191","LU2399975544.HKD","09995","BK1515","BK1161","LU1720050803.USD","09926","IE00B5MMRT66.SGD","LU1969619763.USD","01672","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2488822045.USD","LU0561508036.HKD","LU0417516571.SGD","LU0348766576.USD","LU0540923850.HKD","LU0348735423.USD","LU2778985437.USD","BK1583","BK1100","09939","BK1574","LU0348827113.USD","06998","LU0634319403.HKD","LU1961090484.USD","LU0417516902.SGD","01477","LU2476274720.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2588071737","title":"深化医药供应链布局 京东健康获安宫牛黄丸双天然全渠道代理权","url":"https://stock-news.laohu8.com/highlight/detail?id=2588071737","media":"砍柴网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588071737?lang=zh_cn&edition=full","pubTime":"2025-12-04 00:00","pubTimestamp":1764777600,"startTime":"0","endTime":"0","summary":"近日，京东健康与青岛海发健康投资控股公司达成战略合作，正式获得安宫牛黄丸双天然全渠道代理权。合作达成后，京东健康将为其旗下安宫牛黄丸提供全渠道代理销售解决方案，依托自身线上线下一体化的医药供应链服务体系，助力该产品覆盖更广泛的市场与用户群体。未来，京东健康将继续以全渠道服务能力为基础，推动医药健康产业的数字化转型，助力合作伙伴实现可持续增长，共同促进医疗健康生态的健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204093341a72290ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204093341a72290ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06618","SGXZ86797644.SGD","BK1571","LU0051755006.USD","BK1161","SGXZ62798434.SGD","BK1583","86618","09939","BK1589","BK1247","BK1515","BK1591","BK1142","LU0456827905.SGD","BK1574","BK1615"],"gpt_icon":0},{"id":"2588046985","title":"河化股份：子公司南松医药产品销往印度、芬兰等国家","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046985","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588046985?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:49","pubTimestamp":1764766172,"startTime":"0","endTime":"0","summary":"请问贵公司子公司南松医药作为全球医药中间体领域的隐形冠军，目前公司生产的中间体医药产品是否与海外国家有合作？公司子公司南松医药是一家专业从事医药中间体系列产品研发、生产和销售的高新技术企业，主要产品除供应境内客户外，还销往中国台湾地区以及印度、芬兰等国家；关于公司的生产经营、未来计划等，请以公司的相关公告为准。公司将持续严格按照有关法律法规的规定和要求履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000953","BK1161","MNDmain","BK0004","09939","BK1574","BK1515","BK0066","BK0010","159938","BK0239","BK0077","BK0071"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0294},{"period":"1month","weight":0.1379},{"period":"3month","weight":-0.1646},{"period":"6month","weight":0.3655},{"period":"1year","weight":0.8857},{"period":"ytd","weight":1.0412}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.184167}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}